Implications of obesity for drug therapy: Limitations and challenges

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 1, 2011, Pages 77-89

  Jain, R ^a   Chung, S M ^a   Jain, L ^a   Khurana, M ^a   Lau, S W J ^a   Lee, J E ^a   Vaidyanathan, J ^a   Zadezensky, I ^a   Choe, S ^a   Sahajwalla, C G ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ATRACURIUM; CIPROFLOXACIN; CISATRACURIUM; CYCLOSPORIN; DALTEPARIN; DIAZEPAM; DIGOXIN; ESTRADIOL; ESTRONE; FOLLITROPIN; FONDAPARINUX; FROVATRIPTAN; GENTAMICIN; ILOPERIDONE; INSULIN ASPART; INSULIN GLULISINE; LORAZEPAM; METHYLPREDNISOLONE; NARATRIPTAN; ORAL CONTRACEPTIVE AGENT; RANITIDINE; SUFENTANIL; TOBRAMYCIN; TRAZODONE; UNINDEXED DRUG; VANCOMYCIN; VERAPAMIL;

BODY MASS; DRUG ABSORPTION; DRUG APPROVAL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; HUMAN; INSULIN RESISTANCE; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW;

ANTI-INFECTIVE AGENTS; BODY WEIGHT; CONTRACEPTIVES, ORAL; DRUG LABELING; DRUG THERAPY; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INTESTINAL ABSORPTION; OBESITY; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

EID: 79959376671     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.104     Document Type: Review

References (83)

1. World Health Organization. Obesity and Overweight. (2011).
2. Centers for Disease Control and Prevention. Overweight and Obesity. (2011). Accessed 10 February 2011.
3. Duffull, S.B., Dooley, M.J., Green, B., Poole, S.G. & Kirkpatrick, C.M. A standard weight descriptor for dose adjustment in the obese patient. Clin. Pharmacokinet. 43, 1167-1178 (2004). (Pubitemid 40013182)
4. Hanley, M.J., Abernethy, D.R. & Greenblatt, D.J. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet. 49, 71-87 (2010).
5. Duflou, J., Virmani, R., Rabin, I., Burke, A., Farb, A. & Smialek, J. Sudden death as a result of heart disease in morbid obesity. Am. Heart J. 130, 306-313 (1995).
6. Drenick, E.J. & Fisler, J.S. Sudden cardiac arrest in morbidly obese surgical patients unexplained after autopsy. Am. J. Surg. 155, 720-726 (1988).
7. Reeder, B.A. et al. The association of cardiovascular disease risk factors with abdominal obesity in Canada. Canadian Heart Health Surveys Research Group. CMAJ 157 (suppl. 1), S39-S45 (1997). (Pubitemid 27316527)
8. Garrison, R.J. & Castelli, W.P. Weight and thirty-year mortality of men in the Framingham Study. Ann. Intern. Med. 103, 1006-1009 (1985). (Pubitemid 16211922)
9. Sjostrom, L.V. Mortality of severely obese subjects. Am. J. Clin. Nutr. 55, 516S-523S (1992).
10. Green, B. & Duffull, S.B. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br. J. Clin. Pharmacol. 58, 119-133 (2004). (Pubitemid 39043992)
11. Cheymol, G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin. Pharmacokinet. 39, 215-231 (2000).
12. Bearden, D.T. & Rodvold, K.A. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin. Pharmacokinet. 38, 415-426 (2000). (Pubitemid 30265261)
13. Sanderink, G.J. et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin. Pharmacol. Ther. 72, 308-318 (2002).
14. Clauson, P.G. & Linde, B. Absorption of rapid-acting insulin in obese and nonobese NIDDM patients. Diabetes Care 18, 986-991 (1995).
15. Greenblatt, D.J., Abernethy, D.R., Locniskar, A., Harmatz, J.S., Limjuco, R.A. & Shader, R.I. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 61, 27-35 (1984). (Pubitemid 14089351)
16. Bowman, S.L., Hudson, S.A., Simpson, G., Munro, J.F. & Clements, J.A. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. Br. J. Clin. Pharmacol. 21, 529-532 (1986). (Pubitemid 17175027)
17. Flechner, S.M., Kolbeinsson, M.E., Tam, J. & Lum, B. The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients. Transplantation 47, 806-810 (1989). (Pubitemid 19139118)
18. Cheymol, G., Weissenburger, J., Poirier, J.M. & Gellee, C. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. Br. J. Clin. Pharmacol. 39, 684-687 (1995).
19. Edelman, A.B., Cherala, G. & Stanczyk, F.Z. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. Contraception 82, 314-323 (2010).
20. Blouin, R.A. & Warren, G.W. Pharmacokinetic considerations in obesity. J. Pharm. Sci. 88, 1-7 (1999). (Pubitemid 29037361)
21. Davis, R.L., Quenzer, R.W., Bozigian, H.P. & Warner, C.W. Pharmacokinetics of ranitidine in morbidly obese women. DICP 24, 1040-1043 (1990).
22. Varin, F., Ducharme, J., Theoret, Y., Besner, J.G., Bevan, D.R. & Donati, F. Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. Clin. Pharmacol. Ther. 48, 18-25 (1990). (Pubitemid 20236198)
23. Cheymol, G. Clinical pharmacokinetics of drugs in obesity. An update. Clin. Pharmacokinet. 25, 103-114 (1993). (Pubitemid 23232390)
24. Caraco, Y., Zylber-Katz, E., Berry, E.M. & Levy, M. Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. Eur. J. Clin. Pharmacol. 47, 525-530 (1995).
25. Blouin, R.A. & Ensom, M.H.H. Special pharmacokinetic considerations in the obese. In Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring 4th edn. (eds. Schentag, J.J., Burton, M.E., Shaw, L.M., & Evans, W.E.) 231-241 (Lippincott Williams & Wilkins, Baltimore, MD, 2006).
26. DrugBank. (2011).
27. Lieber, C.S. CYP2E1: from ASH to NASH. Hepatol. Res. 28, 1-11 (2004). (Pubitemid 38145781)
28. Buechler, C. & Weiss, T.S. Does hepatic steatosis affect drug metabolizing enzymes in the liver? Curr. Drug Metab. 12, 24-34 (2011).
29. US Food and Drug Administration. CDER/CBER. Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. (2006).
30. O'Shea, D., Davis, S.N., Kim, R.B. & Wilkinson, G.R. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin. Pharmacol. Ther. 56, 359-367 (1994). (Pubitemid 24339082)
31. Emery, M.G. et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 38, 428-435 (2003). (Pubitemid 36919864)
32. Kotlyar, M. & Carson, S.W. Effects of obesity on the cytochrome P450 enzyme system. Int. J. Clin. Pharmacol. Ther. 37, 8-19 (1999). (Pubitemid 29043392)
33. Abernethy, D.R., Divoll, M., Greenblatt, D.J. & Ameer, B. Obesity, sex, and acetaminophen disposition. Clin. Pharmacol. Ther. 31, 783-790 (1982).
34. Boullata, J.I. Drug disposition in obesity and protein-energy malnutrition. Proc. Nutr. Soc. 69, 543-550 (2010).
35. Honiden, S. & McArdle, J.R. Obesity in the intensive care unit. Clin. Chest Med. 30, 581-99, x (2009).
36. J acques, K.A. & Erstad, B.L. Availability of information for dosing injectable medications in underweight or obese patients. Am. J. Health. Syst. Pharm. 67, 1948-1950 (2010).
37. Anastasio, P. et al. Glomerular filtration rate in severely overweight normotensive humans. Am. J. Kidney Dis. 35, 1144-1148 (2000). (Pubitemid 30354419)
38. Henegar, J.R., Bigler, S.A., Henegar, L.K., Tyagi, S.C. & Hall, J.E. Functional and structural changes in the kidney in the early stages of obesity. J. Am. Soc. Nephrol. 12, 1211-1217 (2001). (Pubitemid 32472634)
39. Nowack, R., Raum, E., Blum, W. & Ritz, E. Renal hemodynamics in recent-onset type II diabetes. Am. J. Kidney Dis. 20, 342-347 (1992).
40. J anmahasatian, S., Duffull, S.B., Chagnac, A., Kirkpatrick, C.M. & Green, B. Lean body mass normalizes the effect of obesity on renal function. Br. J. Clin. Pharmacol. 65, 964-965 (2008). (Pubitemid 351677429)
41. Naumnik, B. & Mysliwiec, M. Renal consequences of obesity. Med. Sci. Monit. 16, RA163-RA170 (2010).
42. J ames, W. Research on Obesity. Her Majesty's Stationery Office, London (1976).
43. J anmahasatian, S., Duffull, S.B., Ash, S., Ward, L.C., Byrne, N.M. & Green, B. Quantification of lean bodyweight. Clin. Pharmacokinet. 44, 1051-1065 (2005). (Pubitemid 41356391)
44. Han, P.Y., Duffull, S.B., Kirkpatrick, C.M. & Green, B. Dosing in obesity: a simple solution to a big problem. Clin. Pharmacol. Ther. 82, 505-508 (2007). (Pubitemid 47622534)
45. Mathijssen, R.H. & Sparreboom, A. Influence of lean body weight on anticancer drug clearance. Clin. Pharmacol. Ther. 85, 23; author reply 24 (2009).
46. Han, P.Y., Duffull, S.B., Kirkpatrick, C.M.J. & Green, B. Response to "Influence of lean body weight on anticancer drug clearance". Clin. Pharmacol. Ther. 85, 24 (2009).
47. Casati, A. & Putzu, M. Anesthesia in the obese patient: pharmacokinetic considerations. J. Clin. Anesth. 17, 134-145 (2005). (Pubitemid 40462234)
48. Choi, J.H. et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466, 451-456 (2010).
49. Wang, E.Q. & Fung, H.L. Effects of obesity on the pharmacodynamics of nitroglycerin in conscious rats. AAPS PharmSci 4, E28 (2002).
50. Derry, C.L., Kroboth, P.D., Pittenger, A.L., Kroboth, F.J., Corey, S.E. & Smith, R.B. Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses in obese and normal-weight men. J. Clin. Psychopharmacol. 15, 197-205 (1995).
51. Bonadonna, R.C., Groop, L., Kraemer, N., Ferrannini, E., Del Prato, S. & DeFronzo, R.A. Obesity and insulin resistance in humans: a dose-response study. Metab. Clin. Exp. 39, 452-459 (1990). (Pubitemid 20156310)
52. Schmid, C., Krayenbuhl, P. & Wiesli, P. Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes. Diabetologia 52, 2668-2669 (2009).
53. Lloret Linares, C.et al. Pilot study examining the frequency of several gene polymorphisms involved in morphine pharmacodynamics and pharmacokinetics in a morbidly obese population. Obes. Surg. (2010); e-pub ahead of print 22 April 2010.
54. Brewer, C.J. & Balen, A.H. The adverse effects of obesity on conception and implantation. Reproduction 140, 347-364 (2010).
55. US Food and Drug Administration. Drugs@FDA database. .
56. PDR Network. Safety Communication Compliance. PDR Electronic Library. (2011).
57. McDowell, M.A., Fryar, C.D., Ogden C.L. & Flegal, K.M. Anthropometric reference data for children and adults: United States, 2003-2006. National Health Statistics Reports. Number 10. (2008).
58. Bonate, P.L. Pharmacokinetic-Pharmacodynamic Modeling and Simulation (Springer, New York, 2006).
59. Prothero, J.W. Organ scaling in mammals: the liver. Comp. Biochem. Physiol. A. Comp. Physiol. 71, 567-577 (1982).
60. Prothero, J. Organ scaling in mammals: the kidneys. Comp. Biochem. Physiol. A. Comp. Physiol. 77, 133-138 (1984).
61. Blouin, R.A., Bauer, L.A., Miller, D.D., Record, K.E. & Griffen, W.O. Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob. Agents Chemother. 21, 575-580 (1982). (Pubitemid 12070524)
62. Bauer, L.A., Edwards, W.A., Dellinger, E.P. & Simonowitz, D.A. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur. J. Clin. Pharmacol. 24, 643-647 (1983). (Pubitemid 13092243)
63. Anderson, B.J. & Holford, N.H. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48, 303-332 (2008). (Pubitemid 351738156)
64. Mahmood, I. Prediction of drug clearance in children: impact of allometric exponents, body weight, and age. Ther. Drug Monit. 29, 271-278 (2007). (Pubitemid 47262255)
65. Westhoff, C.L. et al. Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial. Obstet. Gynecol. 116, 275-283 (2010).
66. Higginbotham, S.; Society of Family Planning. Contraceptive considerations in obese women: release date 1 September 2009, SFP Guideline 20091. Contraception 80, 583-590 (2009).
67. Dinger, J., Minh, T.D., Buttmann, N. & Bardenheuer, K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet. Gynecol. 117, 33-40 (2011).
68. Trussell, J., Schwarz, E.B. & Guthrie, K. Obesity and oral contraceptive pill failure. Contraception 79, 334-338 (2009).
69. Brunner Huber, L.R. & Toth, J.L. Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth. Am. J. Epidemiol. 166, 1306-1311 (2007). (Pubitemid 350129421)
70. Edelman, A.B. et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. Contraception 80, 119-127 (2009).
71. Westhoff, C.L., Torgal, A.H., Mayeda, E.R., Pike, M.C. & Stanczyk, F.Z. Pharmacokinetics of a combined oral contraceptive in obese and normalweight women. Contraception 81, 474-480 (2010).
72. Cherala, G. & Edelman, A. BMI, pharmacokinetics, and OCP failure. Contraception 82, 582; reply 581-582; reply 582 (2010).
73. Doose, D.R., Wang, S.S., Padmanabhan, M., Schwabe, S., Jacobs, D. & Bialer, M. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 44, 540-549 (2003).
74. Pomp, E.R., le Cessie, S., Rosendaal, F.R. & Doggen, C.J. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br. J. Haematol. 139, 289-296 (2007). (Pubitemid 47493087)
75. Abdollahi, M., Cushman, M. & Rosendaal, F.R. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb. Haemost. 89, 493-498 (2003). (Pubitemid 36329240)
76. Bray, G.A. Obesity and reproduction. Hum. Reprod. 12 (suppl. 1), 26-32 (1997).
77. Ramsay, J.E., Greer, I. & Sattar, N. ABC of obesity. Obesity and reproduction. BMJ 333, 1159-1162 (2006).
78. Natazia [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals, 2010. .
79. Implanon [prescribing information]. Oss, The Netherlands: N.V. Organon,. 2006. .
80. Ortho Evra [prescribing information]. Manati, Puerto Rico: Janssen Ortho,. 2001. .
81. Lambrinoudaki, I. et al. EMAS position statement: managing obese postmenopausal women. Maturitas 66, 323-326 (2010).
82. Vance-Bryan, K., Guay, D.R., Gilliland, S.S., Rodvold, K.A. & Rotschafer, J.C. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob. Agents Chemother. 37, 436-440 (1993). (Pubitemid 23072585)
83. Hollenstein, U.M., Brunner, M., Schmid, R. & Muller, M. Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weightadjusted dosing. Int. J. Obes. Relat. Metab. Disord. 25, 354-358 (2001). (Pubitemid 32209810)